EUVIMEDEUVIMED entdecken
Crossref

Targeting Liver Fibrosis with Nanoparticle Technology: The Dual-Drug Strategy for Hepatic Stellate Cell Activation Inhibition

Panyi Hu, Liping Su, Yongchao Wang, Yongqiang Chen, Xiaohe Tian iD, Yeben Qian iD

ACS Applied Materials & Interfaces · 30.04.2025 · 17 (17) · 25071-25082

DOI: 10.1021/acsami.5c02796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 16.04.2025. Verfasst von Panyi Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui, People's Republic of China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, Nanoparticles, Curcumin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Collaborative Innovation Project of Colleges and Universities of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsLiver CirrhosisNanoparticlesCurcuminAntifibrotic AgentsAnimalsMiceCarbon TetrachlorideMaleApoptosisPeptides, CyclicMice, Inbred C57BLFlavonesHumans

Stichwörter der Autor:innen

Activated hepatic stellate cellsCurcuminDihydromyricetinLiver fibrosisNanoparticle

Substanzen

Carbon TetrachlorideCurcuminPeptides, CyclicFlavonescyclic arginine-glycine-aspartic acid peptideAntifibrotic Agents

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui, People's Republic of China.
  • State Key Laboratory of Biotherapy, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, Sichuan University, Chengdu 610000, Sichua…

ORCID-Profile: Xiaohe Tian, Yeben Qian

Förderung

  • Collaborative Innovation Project of Colleges and Universities of Anhui Province

Zitieren

APA

Hu, P., Su, L., Wang, Y., Chen, Y., Tian, X., & Qian, Y. (2025). Targeting Liver Fibrosis with Nanoparticle Technology: The Dual-Drug Strategy for Hepatic Stellate Cell Activation Inhibition. ACS Applied Materials & Interfaces, 17(17), 25071-25082. https://doi.org/10.1021/acsami.5c02796

Vancouver

Hu P, Su L, Wang Y, Chen Y, Tian X, Qian Y. Targeting Liver Fibrosis with Nanoparticle Technology: The Dual-Drug Strategy for Hepatic Stellate Cell Activation Inhibition. ACS Applied Materials & Interfaces. 2025;17(17):25071-25082. doi:10.1021/acsami.5c02796

BibTeX
@article{Hu2025,
  author = {Hu, Panyi and Su, Liping and Wang, Yongchao and Chen, Yongqiang and Tian, Xiaohe and Qian, Yeben},
  title = {Targeting Liver Fibrosis with Nanoparticle Technology: The Dual-Drug Strategy for Hepatic Stellate Cell Activation Inhibition},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  volume = {17},
  number = {17},
  pages = {25071--25082},
  doi = {10.1021/acsami.5c02796}
}
Kostenlos starten →